


Cite this: *RSC Adv.*, 2020, 10, 3092

Mass spectrometry-based metabolomics in health and medical science: a systematic review

Xi-wu Zhang, Qiu-han Li, Zuo-di Xu and Jin-jin Dou*

Metabolomics is the study of the investigation of small molecules derived from cellular and organism metabolism, which reflects the outcomes of the complex network of biochemical reactions in living systems. As the most recent member of the omics family, there has been notable progress in metabolomics in the last decade, mainly driven by the improvement in mass spectrometry (MS). MS-based metabolomic strategies in modern health and medical science studies provide innovative tools for novel diagnostic and prognostic approaches, as well as an augmented role in drug development, nutrition science, toxicology, and forensic science. In the present review, we not only introduce the application of MS-based metabolomics in the above fields, but also discuss the MS analysis technologies commonly used in metabolomics and the application of metabolomics in precision medicine, and further explore the challenges and perspectives of metabolomics in the field of health and medical science, which are expected to make a little contribution to the better development of metabolomics.

Received 31st October 2019
Accepted 14th December 2019

DOI: 10.1039/c9ra08985c

rsc.li/rsc-advances

1 Introduction

Metabolomics is a post-genomics discipline that combines high-throughput analysis techniques with bioinformatics, aimed at establishing high-speed, high-throughput, and comprehensive analysis of metabolites in biological samples. In the past two decades, great breakthroughs have been made in metabolomics that have propelled its evolution into an important tool in the field of medicine, especially in the study of disease-related biomarkers, toxicology, molecular mechanisms, or to provide more detailed information on human biochemistry.^{1,2} The science of metabolic phenotypes is beginning to show real value in explaining clinical and biological problems.^{3,4}

One main advantage of metabolomics is its ability to detect responses even when growth phenotypes are lacking, thus increasing functional readouts by orders of magnitude compared with traditional chemical or genetic growth screening. In any case, by revealing the composition, interaction or change of metabolites, the state of a given system can be described. Metabolomics can be a powerful tool for describing complex phenotypes and evaluating unique physiological responses.

The two main analytical techniques for metabolic analysis are ¹H nuclear magnetic resonance (NMR) and MS. Both of these techniques can analyze a large number of small molecules coexisting in complex samples, including metabolite identification and quantification. NMR spectroscopy can directly

identify and quantitatively analyze numerous analytes. Although the reproducibility of NMR is better than that of MS-based techniques, the sensitivity of NMR is lower and a larger sample size is required. In the field of medical science, clinical samples are particularly valuable; thus MS-based metabolomic technology is widely used in clinical research.⁵

In this review, multiple MS-based analytical platforms for metabolomics are summarized, and the applications of metabolomics in health and medical fields are systematically introduced (Fig. 1). Furthermore, we discuss its limitations and provide a perspective for future developments in MS-based metabolomics.

2 The dilemma of health and medical science

The major health problems are no longer nutritional deficiencies, but how to promote health, how to effectively prevent diseases in advance, as well as the establishment and implementation of individualized therapies. Besides physical exercise to improve health, improvements in personal nutrition should also be strengthened. The focal point of disease prevention is to avoid the causes of the risk factors of disease, which mainly include three categories: primary prevention focuses on the various determinants around the entire population or high-risk groups. Secondary prevention comprises early detection and intervention. The third prevention objective is to improve recovery rates and reduce the risk of recurrence.

As mentioned above, human health depends not only on genes, but also on the interaction of genes with different factors (lifestyle, environment, intestinal microflora, etc.). How to

Institute of Chinese Medicine, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin 150040, China. E-mail: doujinjin1980@126.com; Fax: +86-451-87266827; Tel: +86-451-87266827






Fig. 1 The application of MS-based metabolomics in health and medical science.

reflect the relationships and laws among them in scientific language is the key point that needs to be clarified at present, which will help us understand diseases, as well as implementing precision medical care.

3 Metabolomics in precision medicine

3.1 Pharmacometabolomics

Pharmacometabolomics is considered to be the youngest and most promising branch of metabolomics.⁶ Pharmacometabolomics uses metabolomics to study the efficacy of drugs and helps us understand the mechanism of action and identify biomarkers associated with the organism's response to drug treatment, and further helps doctors predict the effectiveness and toxicity of therapeutic drugs to individuals.^{7–9} It can be used to monitor the body's response to drugs, and the response to a variety of external factors, which allows researchers to assess the drug's effectiveness and the patient's disease status. Therefore, it may be used to better define the mechanisms associated with different drug reactions in patients. Pharmacometabolomics is an effective complement to therapeutic drug monitoring (TDM) in clinical individualized drug therapy. TDM can be used to establish initial dosage regimens and to monitor drugs, while pharmacometabolomics can monitor a drug's levels and metabolites, and effectively predict the efficacy and toxicity of drugs, thus avoiding adverse reactions.¹⁰ A typical schematic diagram of pharmacometabolomic support for precision medicine is shown in Fig. 2.

3.2 Precision medicine

With the continuous progress in medical treatment, the heterogeneity of disease is widely accepted; in other words, the

same disease might have different effects on different individuals. One area in which metabolomics affects precision medicine is in drug response and monitoring. Since drug metabolism involves various enzymes, multiple organs, and varies with gender, age, diet, *etc.*, it will be very difficult to predict the drug response of an individual based on genotype alone.^{10,11} Nevertheless, metabolomics can assess the sum of genotype, environmental and physiological effects, and can be applied to directly monitor drug reactions as well as to determine drug doses. The aim of metabolomics is not only to find novel diagnostic biomarkers to enable the early detection of disease, but also to find appropriate biomarkers for the selection of appropriate interventional therapies and the rational evaluation of current therapeutic responses.^{12,13} These characteristics of metabolomics provide a powerful tool for precision medicine. Metabolomics can reflect the interaction between the genetic and environmental effects of a downstream metabolic phenotype at a specific time.

3.3 Clinical applications of metabolomics in precision medicine

Pharmacometabolomics has yielded certain exciting and medically useful results in drug dosage and response measurement. For instance, in the field of breast cancer treatment, an MS-based pharmacometabolomics for monitoring tamoxifen and its metabolites was used to predict the side effects and discontinuation rate.¹⁴ Side effects have been considered to be a significant predictor of tamoxifen discontinuation; thus, there is a need for reliable predictive factors of side effects of the anti-estrogen treatment.¹⁵ In the present study, over a 6 year period, longitudinal serum samples, patient-reported outcome measures and pharmacy records from 220 breast cancer patients were obtained. The serum concentrations of tamoxifen metabolites were measured by LC-MS/MS. After 2 years of follow up, a high concentration of tamoxifen, Z-4'-OHTam and tam-NoX had a profound association with vaginal dryness. This real-world data study suggested the pharmacometabolomic-based drug monitoring might be a helpful instrument for predicting side effects. A similar method also arose for drug monitoring in patients with Alzheimer's disease, whose dosage monitoring and drug efficacy are often difficult to estimate.¹⁶

Spironolactone is the most effective drug for the treatment of resistant hypertension (RH), but there are differences between patients, as not all patients show a response, and the side effects are not negligible. M. Martin-Lorenzo *et al.* explored a metabolic prediction of treatment response.¹⁷ Urine was collected from 29 patients with RH and 13 patients with pseudo-RH. Samples were collected before and after administration of spironolactone, and RH patients were further classified as responders or non-responders. The contents of citrate and oxaloacetate were increased in RH patients, and together with α -ketoglutarate and malate, these 4 significantly changed metabolites showed an ability to discriminate between responders and non-responders with the area under curve (AUC) being 0.96. The results suggested that a disorder in the






Fig. 2 Schematic diagram of pharmacometabolomic support for precision medicine.

citric acid cycle and reactive oxygen species homeostasis control remained activated after the development of hypertension. A metabolomics study showed the changes before spironolactone treatment and predicted the future reactions of patients, and these markers will help to optimize the treatment with spironolactone in RH patients.

4 Analytical techniques employed in MS-based metabolomics

MS is widely used in metabolomics due to its better sensitivity, high throughput, and its ability to detect more molecules in complex biological samples. The continuous development of MS technology is an important driving force for the development of metabolomics. Here we give a brief overview of three commonly used MS techniques in metabolomics, and Table 1

gives a brief comparison of these three MS-based metabolomic technologies.

4.1 Gas chromatography-mass spectrometry (GC-MS)

GC-MS is the most mature chromatographic-MS technology.¹⁸ Compared with other technologies, GC-MS has the advantages of being relatively inexpensive and easy to operate, and better stability and repeatability. The principle of GC-MS determines that GC-MS can only analyze volatile substances or substances which are easily volatilized after derivatization. The most classical derivation method of GC-MS is the two-step method: oxidation and silylation. The derivatization reaction contributes to the isolation and detection of metabolites.¹⁹ With the derivatization, GC-MS can also be used to analyze not only volatile and non-polar compounds, but also polar compounds such as fatty acids, amino acids, amines, sterols, and sugars.^{20,21} GC-MS has various commercial databases, such as NIST²² and Fiehn,²³

Table 1 A brief comparison of different MS-based metabolomic technologies

Technology	Advantages	Disadvantages
GC-MS	<ul style="list-style-type: none"> • Mature technology • Comparatively cheap • Excellent separation reproducibility • Suitable for the detection of volatile metabolites • Universal databases facilitate metabolite identification 	<ul style="list-style-type: none"> • Requires sample derivatization • Relatively long time for sample analysis • Unable to produce parent ions • Novel compound identification is difficult
LC-MS	<ul style="list-style-type: none"> • Excellent sensitivity • Simple sample pretreatment process • Wide coverage of metabolite detection • Relatively short time for sample analysis with sub-2 μm stationary phase particles • Matching with multiple MS detectors 	<ul style="list-style-type: none"> • Comparatively expensive • Lower reproducibility than GC-MS • Not compatible with volatile metabolites • Novel compound identification is difficult
IMS	<ul style="list-style-type: none"> • <i>In situ</i> detection • Providing location information of metabolites 	<ul style="list-style-type: none"> • Ion suppression • Imaging quality is affected by resolution • Relatively long time for sample analysis



which contain standardized EI source fragmentation information that can be considered to be its unique advantage over other MS-based technologies.²⁴ A spectrum library search not only allows the direct identification of unknown compounds but also helps the characterization of chemical types or groups with similar structures to known constituents.

4.2 Liquid chromatography-mass spectrometry (LC-MS)

Due to different ion sources and working modes of GC-MS and LC-MS, the data forms of the two platforms are also different. As to different ion scanning ranges, the data volume obtained by GC-MS is usually less than that for LC-MS. In addition, LC-MS has a higher tolerance to volatility, a wider metabolite coverage, and simpler approaches to sample preparation. Especially with the advent of UPLC, the separation degree, peak capacity and sensitivity have been greatly improved, and can withstand higher pressures in the range of 6000–19 000 psi.^{25,26} At present, the UPLC system is the mainstream technology used in metabolomic research. Different chromatographic columns can be selected according to the polarity of the analytes. A reversed-phase chromatographic column can be used to analyze lipid-soluble metabolites, such as C₁₈ or C₈ stationary phases. Currently, most UPLC-MS-based metabolomic research has been carried out with a C₁₈ column.²⁷ However, some highly polar and charged metabolites are difficult to retain in a C₁₈ column; thus, a hydrophilic chromatographic column is used to analyze hydrophilic metabolites. In addition, 2-dimensional/multi column approaches can be used to obtain more information about metabolites.²⁸

4.3 Imaging mass spectrometry (IMS)

Metabolite imaging involves the *in vivo* or *in vitro* detection and visualization of metabolites in tissues or cells. Whereas MS-based imaging techniques are usually used in *in vitro* detection. Imaging mass spectrometry (IMS) has been developed and applied to analyze the spatial distribution of chemical composition and molecular mass, and this is a relatively exciting and novel metabolomic technology. By using IMS, the spatial distribution of metabolites in tissues or cells can be visualized. Matrix assisted laser desorption ionization (MALDI) IMS is currently the most common commercial IMS mode, with the highest *m/z* range of 500 kDa and a spatial resolution of 20 μ m. Continuing developments in MALDI-based imaging, such as matrix-free approaches, faster scan rates and smaller spot size, and improved software, have resulted in more explicit images with wider metabolite coverage.²⁹ It seems that IMS might revolutionize the field of histology, just as immune-fluorescence staining did in the 1990s.

The IMS technique may serve as a powerful tool to visualize the distribution of endogenous metabolites over time and space. MALDI imaging has been combined with MRI in the diagnosis of colon cancer, and can also be extended to whole-body imaging of vinblastine, such as in rats.³⁰ IMS technology has become a high-throughput molecular histological research tool for molecular localization and function recognition. Through comprehensive and high-throughput characterization

of metabolic changes in micro regions, IMS technology provides a new method and perspective for the study of metabolic mechanisms in disease. It is worth noting that the key challenges in MS imaging include: sample preparation (including optimization of cell fixation), statistical analysis of large datasets, and the balance between spatial resolution of tissue slice imaging and sensitivity of analyte detection.

In addition to the extensively used MS techniques mentioned above, some other platforms have also made significant progress in metabolomic applications, such as direct injection MS³¹ and capillary electrophoresis-mass spectrometry (CE-MS).³² Since there is no universal MS analytical technique for measuring each metabolite, users should choose the most suitable instrument for their research, and according to demand, give this comprehensive consideration, including resolution, sensitivity, throughput and cost.

The development of these MS-based metabolomic technologies has had a significant impact on several areas of biomedicine, with these advances not only making metabolomics more accessible and powerful, but also altering our understanding of disease, methods of drug discovery, and perspectives on the means of providing health care.

5 Application of MS-based metabolomics in medical science

Unlike other “omics” sciences, metabolomics can link both gene and environmental interactions. It represents not only the downstream output of the genome, but also the upstream input of the environment.³³ In recent years, metabolomics has been applied in multiple fields, on account of its capability of detecting subtle changes in large datasets through comprehensive metabolic measurements. In general, MS-based metabolomics is a valuable implement in medical science, such as clinical biomarker discovery, drug development, nutrition science, toxicology, and forensic science.

5.1 Metabolomic analysis for clinical biomarker discovery

Success in treatment depends on the extent to which the disease is transmitted to the body, such as the stage of the disease; therefore, the early diagnosis of disease is particularly important. The life expectancy of patients can be improved by identifying specific biomarkers for disease diagnosis in the initial stage of a disease. Diagnosis of disease usually requires invasive examination, such as biopsies, or computed tomography scans, for which patients usually consider their radiation exposure. In 1846, the first tumor marker – the Bence Jones protein, confirmed by H. Bence-Jones – had a diagnostic value for multiple myeloma. But early diagnosis is not always feasible because the disease sometimes lacks typical clinical symptoms.³⁴ One hundred years later, with the development of metabolomics, efficient screening of biomarkers has become a great possibility.³⁵ Biomarkers have prospects for broad clinical application, including the following aspects: screening/diagnosis/detection, prognosis and prediction, and monitoring disease progress.^{35–37} Successful screening of biomarkers



is very beneficial to clinics. It can provide prognostic information about disease outcomes, select and evaluate targeted therapies, and provide early intervention for patients, to help clinical decision-making and improve clinical outcomes. Herein, we briefly introduce the key developments in the discovery of clinical biomarkers in the past few years with MS-based metabolomic technologies that might pioneer clinical biomarkers in the future. Furthermore, the process of discovering clinical biomarkers based on MS-based metabolomics is summarized as Fig. 3.

5.1.1 Cardiovascular diseases. Coronary artery disease (CAD) is known to be the premier killer of human health. Its morbidity and mortality rate are increasing year by year, and showing a trend towards younger patients.³⁸ Early intervention is an important means to treat CAD, and early diagnosis is the premise of early intervention. Fan *et al.*, relying on a large sample cohort ($n = 2324$) from clinical multi-centers for CAD and employing MS-based metabolomics techniques and bioinformatics tools, identified 89 differential metabolites from nearly 2000 metabolites closely related to the phenotypic characteristics of the occurrence and development of CAD.³⁹ Furthermore, 12 groups of biomarkers with high sensitivity ($>85\%$) and high specificity ($>85\%$) were screened from the above differential metabolites. The plasma metabolomic characteristics of CAD and its clinical stages (nonobstructive coronary atherosclerosis, stable angina pectoris, unstable angina pectoris, myocardial infarction) were profiled. This study provided important guidance for a further understanding of the occurrence and development, early diagnosis, prognosis, precise treatment and drug response of CAD. In addition, the newly discovered plasma metabolic biomarkers of CAD will offer a new diagnostic basis for clinical transformation. As the early diagnosis technology of CAD based on the present study has the advantages of being fast and non-invasive with high

diagnostic accuracy, it is expected to be widely used in the early diagnosis of CAD and early warning for a high-risk population.

5.1.2 Central nervous system diseases. Alzheimer's disease (AD), has been recognized as one of the most difficult medical problems, with a heavy social and economic cost.⁴⁰ The World Alzheimer's Report has estimated there are more than 46 million AD patients worldwide, with an expected increase to 130 million by 2050.^{40–42} Given that brain pathology precedes clinical symptoms, Kim *et al.* performed MS-based metabolomics to detect whether metabolites in plasma were pathologically related, like cerebrospinal fluid (CSF).⁴³ Healthy individuals ($n = 242$), patients with mild cognitive impairment ($n = 236$), and patients with AD-type dementia ($n = 115$) were included, and logistic regressions were employed to study the relationships between plasma metabolites, CSF markers, magnetic resonance imaging, and cognitive and clinical diagnosis. A panel of primary fatty acid amides, lipokines, and amino acids were associated with amyloid β and t-tau in CSF. It was also confirmed that primary fatty acid amides, aspartate and glutamate were also associated with hippocampal volume and memory. Amyloid protein and tau in CSF are widely accepted as biomarkers for AD. But the process of collecting CSF is complex, and it also brings pain and inconvenience to the patient. The plasma metabolites obtained in this study were associated with multi-dimensional data to characterize AD-related biomarkers, providing the possibility for early diagnosis of AD in the clinic.

5.1.3 Kidney disease. The early stage of chronic kidney disease (CKD) shows almost no signs or symptoms, and the disease cannot be detected until a later stage.⁴⁴ Conventional clinical markers for CKD, such as glomerular filtration rate and albuminuria, are inefficient in assessing the clinical risk of early CKD,⁴⁵ and there is an urgent need for better evaluation of renal function to improve the accuracy of CKD diagnosis. Chen *et al.* recruited four cohorts of 2155 participants to screen potential




Fig. 3 The discovery process of clinical biomarkers based on MS-based metabolomics.



early CKD biomarkers using MS-based metabolomics.⁴⁶ A variety of statistical analysis methods were used, and five metabolites, 5-methoxytryptophan, canavaninosuccinate, acetylcarnitine, tiglylcarnitine, and taurine, can be used to differentiate early CKD patients from healthy controls with an excellent classification effect. The predictive classification ability of the five metabolites was further validated with external and longitudinal cohorts. Three drugs were further used to treat CKD patients to verify the early warning ability of these five metabolites. Four metabolites, with the exception of taurine, were recovered significantly, suggesting the effectiveness of these five metabolites in the diagnosis of early CKD. In this study, metabolomics and large-scale cohort studies were used to identify clinical biomarkers for CKD, and a potential new target, tryptophan hydroxylase-1, may serve as a target for the treatment of CKD. The metabolites screened in the present study will improve existing clinical markers, and provide a scientific basis for drug development and clinical application for CKD.

5.1.4 Liver diseases. Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world and the third most lethal.⁴⁷ Although its risk factors (such as liver cirrhosis) have been widely recognized, the early diagnosis of HCC in a high-risk population is still challenging due to the absence of obvious clinical symptoms in the early stages, the difficulty in a differential diagnosis of cirrhosis, and its rapid development and easy metastasis.⁴⁸ It is urgent to develop a new, stable and reliable method for the early screening of HCC. A total of 1448 subjects, including healthy controls, and patients with chronic hepatitis B, liver cirrhosis and HCC were enrolled in a study by Luo *et al.*⁴⁹ Based on LC-MS-based metabolomics, a new panel of metabolic markers for HCC was identified and validated: phenylalanyl-tryptophan and glycocholate. The results of large-scale clinical trials showed that the above panel could effectively detect HCC in high-risk patients with liver cirrhosis, with an AUC of 0.807–0.930, which was superior to α -fetoprotein (AFP, with an AUC of 0.65–0.725), a traditional clinical marker for HCC, and it had good complementarity with AFP. The combined application of the panel and AFP can effectively avoid AFP false-negative patients with HCC, and the diagnostic accuracy could be 80.6–100%. Furthermore, the panel can be used to distinguish small HCC from patients with liver cirrhosis (AUC: 0.753–0.866). Two other cancers, gastric cancer (GSC) and intrahepatic cholangiocarcinoma (ICC), were further used to assess the specificity of the potential panel for HCC. The results showed that HCC can be differentiated from GSC and ICC with AUC of 0.946 and 0.829, which indicated the specificity of the panel for HCC. The data from Cohort 2 of the validation set showed that the panel can provide a risk prediction for a high-risk population one year before the occurrence of HCC (AUC: 0.79), and the combination with AFP can further improve the prediction accuracy (AUC: 0.88). This is of great significance for the surveillance of patients with pre-clinical HCC.

5.1.5 Lung disease. Lung cancer (LCA) is the leading cause of cancer-related deaths in both men and women worldwide,⁵⁰ and most LC patients present with inoperable and poor prognosis.⁵¹ Ren *et al.* established a matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)-based metabolomics

to simultaneously and directly quantify serum nonesterified and esterified fatty acids (TFA) from 1440 serum samples of 487 healthy controls, 479 patients with benign lung diseases and 474 patients with LCA.⁵² No significant difference was found in TFA contents between different genders, but those of different ages were different. Receiver operating characteristic analysis revealed that 3 groups of panels displayed a higher diagnostic ability than that of carcinoembryonic antigen (CEA) or Cyfra 21-1, the best known tumor markers for LCA.⁵³ The advantage of this study is that it simultaneously compared the diagnostic ability of commonly used tumor markers while screening potential markers, which offered a stepping stone for a new biomarker for benign lung diseases and LCA.

5.1.6 Pancreatic diseases. Due to delayed diagnosis and the lack of new treatment methods, pancreatic cancer may be the third leading cause of cancer-related death by 2030.⁵⁰ At present, the 5 year survival rate from pancreatic cancer is about 6%. Early detection of pancreatic cancer and surgical resection can improve the survival rate by 30% to 40%.⁵⁴ Carbohydrate antigen 19-9 (CA 19-9) is the only blood biomarker currently used in pancreatic cancer.⁵⁵ The “metabolic dynamic images” of metabolomics have been used to identify new biomarkers of blood metabolites that can distinguish pancreatic cancer from chronic pancreatitis, which were more sensitive than traditional diagnostic methods and were suitable for earlier stages of the disease.⁵⁶ This study used the largest ever sample of patients with pancreatic diseases ($n = 914$) to identify the characteristics of tumor biomarkers in pancreatic cancer and chronic pancreatitis using a metabolomic approach. The biomarkers identified in this study improved the diagnostic accuracy of the resectable stages of pancreatic cancer (AUC of 0.96, sensitivity of 89.9%, specificity of 91.3%), and treatment stratification in comparison to CA 19-9.

5.1.7 Osteoarthritis. Osteoarthritis (OA) is the most common musculoskeletal disease in the world, and can lead to increasing disability.⁵⁷ There are currently no effective drugs to treat OA or to protect joints from degeneration.⁵⁸ Since OA has a significant impact on a patient's health and quality of life, the prevention and treatment of OA are urgently needed. Progress in the diagnosis of OA is mainly based on imaging examination. Nevertheless, radiography only offers structural information on damaged bone and cartilage, not pathophysiological information related to different clinical phenotypes. If the biomarkers of OA can be identified before the irreversible phase arrives, this situation will be improved. A urinary metabolomics study based on GC-MS in combination with multivariate statistics was used to produce a classification to differentiate between knee OA, in two different OA phenotypes, and healthy controls, by Li *et al.*⁵⁹ A lower level of histidine and a higher level of histamine were found in OA2 patients (a positive value for the patellar ballottement test indicates knee effusion) as compared with OA1 patients (for which the patellar ballottement test is negative). It was intended to use the above result to explore an alternative means for the diagnosis and stratification of OA patients. This non-invasive method for defining and identifying sub-classes of OA would be of great significance for prognosis, personalized treatment, and clinical evaluation of OA.



5.1.8 Diabetes. Rebholz *et al.* prospectively analysed metabolites by an untargeted metabolomic approach from 2939 participants, 1126 of whom had diabetes.⁶⁰ Among the identified metabolites, seven (isoleucine, asparagine, leucine, 3-(4-hydroxyphenyl)lactate, valine, trehalose and erythritol) were significantly associated with incident diabetes, which modestly improved the prediction of incident diabetes beyond fasting glucose and established risk factors. This was the first report of asparagine as a protective biomarker for diabetes risk, which also offered strategies for the precision treatment of diabetes. The serum metabolomics indicated a novel metabolic disturbance that might improve the prediction of diabetes.

Metabolic phenotypes provide a new dimension in patient information, enabling patients to be stratified according to their metabolic profiles. Biomarkers for the diagnosis and prognosis of disease can play an important role in individualized treatment and precision medicine. Although the development prospects of biomarkers are tremendous, there are still many problems in the current stage. First, it is essential to select preclinical samples for biomarker detection. Large-scale, multi-center and comprehensive clinical information is a necessary factor. However, due to the cost and availability of samples, these classical large-scale cohort studies often use a single time point sample for metabolomic research. Samples of sequential points can increase the reliability of the results and contribute to research into disease progression. Moreover, although effective biomarkers are being used in clinical practice, such as carbohydrate antigen 125 for the early diagnosis of ovarian cancer and serum creatinine as an indicator of renal function,⁶¹ the development of these markers requires years and large-scale, multidisciplinary efforts. Among numerous potential biomarkers, less than 1% entered clinical practice.⁶² This not only indicates that it is very difficult to convert biomarkers into practical clinical applications, but their discovery and development are similar to drug discovery, and this is a great challenge, requiring a large amount of financial investment, rigorous science and technology, as well as networks of clinicians, biologists, specialists in bioinformatics, statisticians, clinical chemists and other experts.

5.2 Metabolomics analysis for drug development

Modern drug development involves many disciplines, including biology, chemistry and pharmacy. Traditional processes are needed to screen drugs in molecular libraries, to optimize hits, and search for molecular affinity, selectivity, metabolic stability, oral bioavailability, *etc.* Only after satisfying the above conditions can a small percentage of molecules enter the stage of being candidate drugs for clinical trials, with some of them eventually failing in phase III trials.⁶³ Metabolomics, as a branch of systems biology, not only discovers exciting opportunities in diagnosis, but the application of toxicity/efficacy biomarkers in drug discovery has significantly accelerated the pace of drug discovery, and contributed to the formulation of appropriate clinical plans. By examining the changes in metabolic disturbances *in vivo* and *in vitro*, metabolomics can provide information on the efficacy and safety of drugs, which

may not be available in other research processes. This function of metabolomics is usually used in preclinical studies of drug development, focusing on the safety of preclinical and translational target engagement biomarkers, as well as playing a vital role in the discovery of drug side effects. Furthermore, the results of a great number of metabolomic studies have broadened the understanding of the complexity and heterogeneity of diseases, thus contributing to the discovery of new targets in drug development.

Metabolomics is often used in drug development to study the function of metabolic enzymes and to identify novel drug targets. Many drugs used clinically are enzyme inhibitors that regulate the activity of metabolic enzymes and maintain metabolic balance. A good example of the application of metabolomics in drug development is Enasidenib and Ivosidenib, two first-class drugs for the treatment of isocitrate dehydrogenase-1 (IDH-1) and IDH-2-mutated recurrence or refractory acute myeloid leukemia (AML). Dang *et al.*⁶⁴ and Ward *et al.*⁶⁵ with the aid of MS-based metabolomics demonstrated that the mutant enzymes of IDH-1 and IDH-2 can convert α -ketoglutarate into 2-hydroxyglutarate, which was considered to be an oncometabolite in glioma and AML. Subsequent studies confirmed that inhibitors of mutant IDH-1 inhibited the production of 2-hydroxyglutarate and the growth of tumors, giving prominence to the value of metabolomics in discovering new therapeutic targets.⁶⁶ After a series of studies and clinical trials, Enasidenib, a new drug treatment for relapsed or refractory AML was approved. Ivosidenib, a sister drug to Enasidenib, an inhibitor for mutant IDH-1, was subsequently approved by the FDA.⁶⁷ Metabolomics has been applied to almost every stage of the development of mutant IDH-1 and IDH-2 inhibitors, and has brought about new therapeutic options for relapsed or refractory AML patients.

5.3 Metabolomics analysis for nutrition science

Epidemiological and clinical studies have provided clear evidence since the 1970s that many diseases with high morbidity and mortality are related to diet, including diabetes, cardiovascular diseases and a range of cancers.⁶⁸ It is known that selected foods, nutrients, and dietary patterns interact with various metabolic processes to reduce or increase the risk of disease: for instance, high salt intake increases blood pressure,⁶⁹ and high red meat intake increases the incidence of type 2 diabetes mellitus,⁷⁰ cardiovascular disease,⁷¹ and cancers.⁷²

Diet, dietary patterns and other environmental factors play a vital role in the prevention and development of many diseases. Food intake is an important environmental factor, because food ingredients may alter gene expression and structural modification, thereby altering the composition of proteins and metabolites. Thus, it is an important part of health-related research. Metabolomics, as an experimental method in nutrition science, is gradually maturing.⁷³ It is a useful method of analysis to reveal dietary changes and related systemic biological results. Nutrition metabolomics has become a high-throughput and sensitive method for identifying and characterizing biochemical pathways.⁷⁴ It is also the basis for revealing



the complex relationship between dietary exposure and chronic diseases with metabolic phenotypic changes.⁷⁵

The emergence of nutritional metabolomics has two main objectives: (1) to determine the effects of dietary compounds on host metabolism within a certain period of time; (2) to determine the biomarkers of dietary intake or phytochemical dose-dependent metabolites.^{76,77} The application of metabolomics in nutrition research can generally be divided into four main fields: identification of dietary biomarkers, identification of dietary-related diseases and disease biomarkers, application of nutrition as a tool to identify molecular mechanisms in dietary intervention research, and precision nutrition.^{78,79} These areas are mainly focused on determining the effects of dietary compounds on the host metabolism after consumption for a certain period of time, and determining biomarkers of metabolites related to dietary intake or phytochemical dose dependence, which have a significant impact on a study of the diet–health relationship.⁸⁰

Compared with traditional dietary assessment methods, the application of metabolomics provides a more objective dietary intake measurement method for the identification of dietary intake biomarkers, which greatly improves our ability to assess dietary intake.⁸¹

At present, the discovery of dietary biomarkers is mainly concentrated on single biomarkers. To give impetus to this area, combinations or panels of biomarkers might provide more accurate measurements of dietary exposure.⁸² The application of metabolomics in dietary intervention research enables researchers to study the mechanism of intervention and thus ascertain the effects of diet/food on metabolic pathways. Precise nutrition can be defined as customized dietary advice for individuals. A recent study showed that personalized dietary recommendations improved individual eating habits in a randomized controlled trial compared with general healthy dietary guidelines,⁸³ showing a vital role in the development and provision of precise nutrition.

Metabolomics has broad prospects for application in nutritional epidemiology, and it is expected that it will play a leading role in explaining the interaction between diet and health. It is necessary to validate the new biomarkers found in a study, and long-term studies are needed to identify dietary biomarkers that reflect habitual dietary intake. Nutrition science will benefit greatly from the appropriate application of metabolomics.

5.4 Metabolomic analysis for toxicology

Metabolomics has gradually expanded from the initial screening of biomarkers for diseases to the field of toxicology research.^{84,85} In toxicology, metabolomics is the most relevant discipline to classical knowledge about disturbed biochemical pathways. It can quickly identify potential targets of dangerous compounds and provide information about target organs, evaluate toxicity changes in organisms from a holistic perspective, predict toxicity and discover toxicity-related biomarkers, which are helpful to improving our understanding of the toxicity mechanisms of given compounds.

Incidents with Yunnan Baiyao and other safety problems with traditional Chinese medicines (TCM) occur frequently,

which seriously hinders the development and clinical application of TCMs. Toxicity and adverse reactions of TCM have become a research hotspot in academia. In virtue of the complex composition of TCM, its multi-component and multi-target mode of action coincides with the ideas of metabolomics, and the use of metabolomics to study the toxicity of TCM has become a prevalent technical method. Yunnan Baiyao is a traditional Chinese prescription with the magical effect of promoting blood clotting and hemostasis. But its clinical application has been widely questioned because it contains the poisonous TCM of *Aconiti kusnezoffii* radix. Correct assessment of the toxicity of Yunnan Baiyao will not only help to eliminate misunderstanding about Yunnan Baiyao, but also promote the development of TCM. Ren *et al.* performed MS-based metabolomics to study the toxic effects of Yunnan Baiyao on normal rats.⁸⁶ According to the results of the study, the toxicity of *Aconiti kusnezoffii* radix was observed earlier than in histopathology. Moreover, by comparing the changes in metabolite callback under the action of *Aconiti kusnezoffii* radix, processed *Aconiti kusnezoffii* radix, Yunnan Baiyao and Yunnan Baiyao lacking *Aconiti kusnezoffii* radix, with a secondary focus on metabolic pathways, the key metabolic pathways that may play a role in attenuation were determined. Furthermore, the compatibility and detoxification effects of Yunnan Baiyao were clarified. However, this study only clarifies one aspect of the mechanism of compatibility and detoxification of Yunnan Baiyao, and corresponding animal models should be established to evaluate the toxicity of Yunnan Baiyao under the effective state of treatment, which will make the study more comprehensive.

A series of clinical and experimental poisoning cases with cinnabar and realgar are related to overdose or long-term use of drugs.⁸⁷ An-gong Niu Huang Wan just contains these two poisonous TCMs; moreover, they are the active ingredients in An-gong Niu Huang Wan for neuroprotection.⁸⁸ Nevertheless, the toxicity of cinnabar and realgar can be reduced by compatibility with other TCMs. Xia *et al.* established an ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC/Q-TOFMS)-based metabolomics approach to reveal the protective role of other herbs in An-gong Niu Huang Wan against the hepatorenal toxicity of cinnabar and realgar.⁸⁹ The results showed that the toxicity of the prescription was lower than that of cinnabar and realgar alone. In addition, other TCMs have anti-inflammatory and attenuation effects by regulating the metabolism of glycerophospholipid, arachidonic acid, linoleic acid, ether lipid and sphingolipid. These studies provide more scientific evidence for the safety of clinical applications of TCM.

5.5 Metabolomics analysis for forensic science

The overall objective of forensic science is to provide tools for all actors involved in criminal investigations and procedures in order to achieve fairer tracking, effective investigation of criminal science, and evidence for prosecution for or elimination from a suspected crime.⁹⁰ The characteristics of most forensic samples are complex and they are available in trace amounts. Sample types include blood, urine, saliva, faeces, tissues, *etc.*,



similar to the samples in metabolomics. Furthermore, MS is undoubtedly a powerful analytical technology better suited to the exigencies of forensic samples and analyte identification.

The identification of endogenous and exogenous chemicals embodied in latent fingerprints is vital for forensic science to obtain evidence of criminal identities and contact with specific chemicals. Groeneveld *et al.* performed a “basics” and the potential of MALDI IMS for the detection of drugs and their metabolites in fingerprints.⁹¹ In this study, 17 compounds from five different categories of drugs, amphetamine, alkaloids, opioids, cannabinoids and specialty drugs, were selected. The number of species included in MALDI-MS profiling and imaging analyses represents the importance of detecting forensic-related substances, such as drug abuse and its metabolites, in pre-developed marks. The overall results showed that, although the drug signal intensity is much lower in many cases, as a pre-development effect, their intensity was still enough to provide an image of the ridge detail. The data presented by this research confirmed the powerful potential of implementing MALDI IMS in forensic casework.

Opiates are derivatives of opium alkaloids, the most representative of which are morphine, codeine and heroin. Heroin is the second most popular recreational drug, more abusers die each year from heroin abuse than from any other illicit drug, and it causes a great many people to commit crimes. With the aid of MS-based metabolomics, heroin abuse and related mechanisms were gradually revealed.⁹² The biomarkers of 6-acetylmorphine, morphine, codeine, codeine-6-glucuronide, 6-acetylcodeine, noscapine, papaverine, and thebaine have been utilized and recommended for obtaining the most reliable forensic results. Furthermore, profound alterations in L-tryptophan, 5-hydroxytryptamine and 5-hydroxyindoleacetate were suggested as potential non-specific biomarkers of long-term heroin addiction.⁹³ The above-mentioned exogenous components and endogenous metabolites will undoubtedly help to reveal a link between metabolic disorders and addiction, with relevant clinical and forensic implications. In light of drug dependence being a highly complex disease, combining reward effects, tolerance, and withdrawal effects, longitudinal studies need to be carried out to approve the aforementioned exogenous components and endogenous metabolites. In addition, with the emergence of new drugs in the clandestine market, and new degradation pathways of existing compounds, it is a great challenge for MS-based metabolomics and a never-ending task for analytical chemists to develop the most appropriate method.

6 Limitations and future perspective

Nowadays, in the medical science field, people have gradually become interested in describing the characteristics of health status at the molecular level in order to develop personalized treatments, early diagnosis, nutritional adjustments and rapid and sensitive detection in forensic science, *etc.* MS-based metabolomics, as a vital part of systems biology, has made remarkable progress in health and medical science. However, limitations and challenges still exist in its continuing exploration.

In clinical research, it is necessary to further explore the effects of race, gender, age, dietary intake, physical activity, intestinal microflora, and stress, so as to promote an understanding of human metabolome, realize the real integration of metabolomics and big data, and thus improve data elucidation. The acquisition speed, accuracy, sensitivity and coverage of MS still require further improvement. New processes for the accurate identification of metabolites, rapid acquisition methods, and novel detection methods with high derivative efficiency should be developed to achieve large-scale coverage of metabolites and to facilitate data processing. Although metabolomics can identify a great quantity of metabolites, researchers usually do not identify metabolites that are not found in databases or websites. The exploration of unknown metabolites is a real challenge and research direction in metabolomics. In addition, some standards are difficult to obtain, and the existence of *cis*- and *trans*-isomers can also lead to inaccurate identification of metabolites. Thus, it is necessary to speed up the construction of standard product databases and information sharing.

Current MS-based metabolomic analysis mostly adopts relative quantification or qualitative analysis with fewer examples of quantitative analysis. The accurate concentration of metabolites *in vivo* has an important influence on the interpretation of metabolite function. How to simultaneously quantify multiple metabolites is the short board of current metabolomics? The ideal state is to use stable isotope-assisted metabolomics to track reaction substrates and determine the role of metabolites in metabolic pathways.⁹⁴ Furthermore, the diversity of many enzyme substrates, in addition to the complexity of metabolic networks, make it difficult to influence the content of a single metabolite without affecting others. This in turn increases the difficulty in assessment of metabolite function. Moreover, we should also pay attention to the analysis of precious/scarcely available samples. The information contained in these samples is of great scientific value, and might be key to solving some difficult problems.

It must be admitted that metabolomics is not a separate discipline, and the future direction of development must be a combination of multiple omics, so as to better understand the biological system. In order to better implement and simplify multi-omics technology, more vigorous computing power and new bio-informatic algorithms need to be developed. For metabolomics, especially for metabolomic technology applied in health and the medical science field, a series of common criteria should be established for metabolomic research design, method optimization and data processing *etc.*, so as to ensure the authenticity and validity of the research and data sharing in different laboratories.

Metabolomics can undoubtedly help accelerate drug development, reducing costs and time. Introducing new biomarkers into existing biomarkers will help to assess disease-related risks, as well as being used in precision medicine, selecting appropriate treatment methods for patients, and monitoring their response to treatment. Metabolomics will also have a great impact on the development of other medical fields, paving the way for new medical strategies. With the development of the medical health industry entering a new era, the emergence and development of new technologies, such as big data, artificial



intelligence and other new technologies, will surely release a huge space for the improvement and optimization of medical services. In the future, automation and artificial intelligence will also enter into the sample preparation process and the complex and massive data analysis process.

7 Conclusion

MS-based metabolomics technology has provided exciting opportunities in the field of health and medical science. As mentioned above, opportunities and challenges coexist. It is believed that, with the continuous progress in technologies, there will be more and more effective biomarkers for the diagnosis of clinical diseases, the widespread implementation of personalized treatment, improvement in national nutrition and physical fitness, the scientific assessment of toxic substances and breakthroughs in forensic medicine. There are grounds to expect that MS-based metabolomics technology will be gradually applied in clinical practice.

Abbreviations

AFP	α -Fetoprotein
AML	Acute myeloid leukemia
AUC	Area under curve
AD	Alzheimer's disease
CA19-9	Carbohydrate antigen 19-9
CAD	Coronary artery disease
CE	Capillary electrophoresis
CEA	Carcinoembryonic antigen
CFS	Cerebrospinal fluid
CKD	Chronic kidney disease
HCC	Hepatocellular carcinoma
ICC	Intrahepatic cholangiocarcinoma
IHD	Isocitrate dehydrogenase
IMS	Imaging mass spectrometry
GC	Gas chromatography
GSC	Gastric cancer
LCA	Lung cancer
LC	Liquid chromatography
MALDI	Matrix assisted laser desorption ionization
MS	Mass spectrometry
NMR	Nuclear magnetic resonance
OA	Osteoarthritis
RH	Resistant hypertension
TCM	Traditional Chinese medicines
TDM	Therapeutic drug monitoring
TFA	Nonesterified and esterified fatty acids

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by grants from the Key Program of Natural Science Foundation of State (Grant No. 81873161), the

Chinese Postdoctoral Science Foundation (2018W631), and the Natural Science Foundation of Heilongjiang Province (H2018050, LH2019H102).

References

- 1 B. Hoher and J. Adamski, Metabolomics for clinical use and research in chronic kidney disease, *Nat. Rev. Nephrol.*, 2017, **13**(5), 269–284.
- 2 C. H. Johnson, J. Ivanisevic and G. Siuzdak, Metabolomics: beyond biomarkers and towards mechanisms, *Nat. Rev. Mol. Cell Biol.*, 2016, **17**(7), 451–459.
- 3 P. D. Rainville, G. Theodoridis, R. S. Plumb, *et al.*, Advances in liquid chromatography coupled to mass spectrometry for metabolic phenotyping, *TrAC, Trends Anal. Chem.*, 2014, **61**, 181–191.
- 4 M. Fessenden, Metabolomics: small molecules, single cells, *Nature*, 2016, **540**(7631), 153–155.
- 5 A. D. Kennedy, B. M. Wittmann, A. M. Evans, *et al.*, Metabolomics in the clinic: a review of the shared and unique features of untargeted metabolomics for clinical research and clinical testing, *J. Mass Spectrom.*, 2018, **53**(11), 1143–1154.
- 6 T. A. Clayton, J. C. Lindon, O. Cloarec, *et al.*, Pharmacometabonomic phenotyping and personalized drug treatment, *Nature*, 2006, **440**(7087), 1073–1077.
- 7 I. Du Preez and D. T. Loots, Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance, *Drug Metab. Rev.*, 2018, **50**(4), 466–481.
- 8 Q. Huang, J. Aa, H. Jia, *et al.*, A Pharmacometabonomic Approach To Predicting Metabolic Phenotypes and Pharmacokinetic Parameters of Atorvastatin in Healthy Volunteers, *J. Proteome Res.*, 2015, **14**(9), 3970–3981.
- 9 A. Backshall, R. Sharma, S. J. Clarke, *et al.*, Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine, *Clin. Cancer Res.*, 2011, **17**(9), 3019–3028.
- 10 R. Kaddurah-Daouk, R. Weinshilboum and Pharmacometabolomics Research N, Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine, *Clin. Pharmacol. Ther.*, 2015, **98**(1), 71–75.
- 11 E. E. Balashova, D. L. Maslov and P. G. Lokhov, A Metabolomics Approach to Pharmacotherapy Personalization, *J. Pers. Med.*, 2018, **8**(3), 28.
- 12 M. Jacob, A. L. Lopata, M. Dasouki, *et al.*, Metabolomics toward personalized medicine, *Mass Spectrom. Rev.*, 2019, **38**(3), 221–238.
- 13 L. Puchades-Carrasco and A. Pineda-Lucena, Metabolomics Applications in Precision Medicine: An Oncological Perspective, *Curr. Top. Med. Chem.*, 2017, **17**(24), 2740–2751.
- 14 T. Helland, K. B. Hagen, M. E. Haugstoyl, *et al.*, Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database, *Breast Cancer Res. Treat.*, 2019, **177**(1), 185–195.



- 15 E. A. Bowles, D. M. Boudreau, J. Chubak, *et al.*, Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer, *J. Oncol. Pract.*, 2012, **8**(6), e149–e157.
- 16 S. Ponnayyan Sulochana, K. Sharma, R. Mullangi, *et al.*, Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease, *Biomed. Chromatogr.*, 2014, **28**(11), 1431–1490.
- 17 M. Martin-Lorenzo, P. J. Martinez, M. Baldan-Martin, *et al.*, Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response, *Hypertension*, 2017, **70**(5), 1049–1056.
- 18 D. J. Beale, F. R. Pinu, K. A. Kouremenos, *et al.*, Review of recent developments in GC-MS approaches to metabolomics-based research, *Metabolomics*, 2018, **14**(11), 152.
- 19 J. M. Halket, D. Waterman, A. M. Przyborowska, *et al.*, Chemical derivatization and mass spectral libraries in metabolic profiling by GC/MS and LC/MS/MS, *J. Exp. Bot.*, 2005, **56**(410), 219–243.
- 20 S. C. Yan, Z. F. Chen, H. Zhang, *et al.*, Evaluation and optimization of sample pretreatment for GC/MS-based metabolomics in embryonic zebrafish, *Talanta*, 2020, **207**, 120260.
- 21 Y. Yang, Y. Yin, X. Chen, *et al.*, Evaluating different extraction solvents for GC-MS based metabolomic analysis of the fecal metabolome of adult and baby giant pandas, *Sci. Rep.*, 2019, **9**(1), 12017.
- 22 Y. Simon-Manso, M. S. Lowenthal, L. E. Kilpatrick, *et al.*, Metabolite profiling of a NIST Standard Reference Material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources, *Anal. Chem.*, 2013, **85**(24), 11725–11731.
- 23 T. Kind, G. Wohlgemuth, D. Y. Lee, *et al.*, FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry, *Anal. Chem.*, 2009, **81**(24), 10038–10048.
- 24 M. Vinaixa, E. L. Schymanski, S. Neumann, *et al.*, Mass spectral databases for LC/MS and GC/MS-based metabolomics: state of the field and future prospects, *TrAC, Trends Anal. Chem.*, 2016, **78**, 23–35.
- 25 J. R. Mazzeo, U. D. Neue, M. Kele, *et al.*, Advancing LC Performance with Smaller Particles and Higher Pressure, *Anal. Chem.*, 2005, **77**(23), 460–467.
- 26 A. F. Nassar, T. Wu, S. F. Nassar, *et al.*, UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research, *Drug Discovery Today*, 2017, **22**(2), 463–470.
- 27 N. L. Kuehnbaum and P. Britz-McKibbin, New advances in separation science for metabolomics: resolving chemical diversity in a post-genomic era, *Chem. Rev.*, 2013, **113**(4), 2437–2468.
- 28 H. Gika, C. Virgiliou, G. Theodoridis, *et al.*, Untargeted LC/MS-based metabolic phenotyping (metabonomics/metabolomics): the state of the art, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2019, **1117**, 136–147.
- 29 J. Sekula, J. Niziol, W. Rode, *et al.*, Gold nanoparticle-enhanced target (AuNPET) as universal solution for laser desorption/ionization mass spectrometry analysis and imaging of low molecular weight compounds, *Anal. Chim. Acta*, 2015, **875**, 61–72.
- 30 P. H. Pevsner, J. Melamed, T. Remsen, *et al.*, Mass spectrometry MALDI imaging of colon cancer biomarkers: a new diagnostic paradigm, *Biomark. Med.*, 2009, **3**(1), 55–69.
- 31 Y. Zhang, L. Qiu, Y. Wang, *et al.*, High-throughput and high-sensitivity quantitative analysis of serum unsaturated fatty acids by chip-based nanoelectrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry: early stage diagnostic biomarkers of pancreatic cancer, *Analyst*, 2014, **139**(7), 1697–1706.
- 32 K. Sasaki, H. Sagawa, M. Suzuki, *et al.*, Metabolomics Platform with Capillary Electrophoresis Coupled with High-Resolution Mass Spectrometry for Plasma Analysis, *Anal. Chem.*, 2019, **91**(2), 1295–1301.
- 33 D. S. Wishart, Emerging applications of metabolomics in drug discovery and precision medicine, *Nat. Rev. Drug Discovery*, 2016, **15**(7), 473–484.
- 34 G. Lubes and M. Goodarzi, GC-MS based metabolomics used for the identification of cancer volatile organic compounds as biomarkers, *J. Pharm. Biomed. Anal.*, 2018, **147**, 313–322.
- 35 M. M. Khamis, D. J. Adamko and A. El-Aneed, Mass spectrometric based approaches in urine metabolomics and biomarker discovery, *Mass Spectrom. Rev.*, 2017, **36**(2), 115–134.
- 36 L. C. Martial, R. E. Aarnoutse, M. Mulder, *et al.*, Dried blood spot sampling in psychiatry: perspectives for improving therapeutic drug monitoring, *Eur. Neuropsychopharmacol.*, 2017, **27**(3), 205–216.
- 37 M. Paulzen, T. W. Goecke, E. Stickeler, *et al.*, Sertraline in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood, *J. Affective Disord.*, 2017, **212**, 1–6.
- 38 M. Shipkova, S. Rapp, R. Rigo-Bonnin, *et al.*, Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method, *Ther. Drug Monit.*, 2017, **39**(2), 102–108.
- 39 Y. Fan, Y. Li, Y. Chen, *et al.*, Comprehensive Metabolomic Characterization of Coronary Artery Diseases, *J. Am. Coll. Cardiol.*, 2016, **68**(12), 1281–1293.
- 40 Z. D. Liu, A. H. Zhang, H. Sun, *et al.*, Two decades of new drug discovery and development for Alzheimer's disease, *RSC Adv.*, 2017, **7**, 6046–6058.
- 41 S. A. Love, J. C. Seegmiller, J. Kloss, *et al.*, Urine Creatinine Concentrations in Drug Monitoring Participants and Hospitalized Patients, *J. Anal. Toxicol.*, 2016, **40**(8), 659–662.
- 42 M. Prince, A. Comas-Herrera, M. Knapp, *et al.*, *World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future*, Alzheimer's Disease International, 2016.



- 43 M. Kim, S. Snowden, T. Suvitaival, *et al.*, Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort, *Alzheimer's Dementia*, 2019, **15**(6), 817–827.
- 44 J. Afonso, S. Lopes, R. Goncalves, *et al.*, Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays, *Aliment. Pharmacol. Ther.*, 2016, **44**(7), 684–692.
- 45 Z. K. Ye, Y. L. Chen, K. Chen, *et al.*, Therapeutic Drug Monitoring of Vancomycin: A Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society, *J. Antimicrob. Chemother.*, 2016, **71**(11), 3020–3025.
- 46 D. Q. Chen, G. Cao, H. Chen, *et al.*, Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan, *Nat. Commun.*, 2019, **10**(1), 1476.
- 47 F. Bray, J. Ferlay, I. Soerjomataram, *et al.*, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *Ca-Cancer J. Clin.*, 2018, **68**(6), 394–424.
- 48 H. B. El-Serag and K. L. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, *Gastroenterology*, 2007, **132**(7), 2557–2576.
- 49 P. Luo, P. Yin, R. Hua, *et al.*, A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma, *Hepatology*, 2017, **67**(2), 662–675.
- 50 D. DiPrinzio and R. Sethi, Will Adding Methadone to Controlled Substance Monitoring Programs Help Psychiatrists Prevent Prescription Drug Overdoses?, *Primary Care Companion for CNS Disorders*, 2016, **18**(2), DOI: 10.4088/PCC.15l01871.
- 51 J. Lock, R. K. Patel, C. Brookes, *et al.*, Clinical Experience of Prescribing Dabigatran Etexilate With Dronedaron: The Role of Therapeutic Drug Monitoring, *Ther. Drug Monit.*, 2016, **38**(6), 813–814.
- 52 J. L. Ren, D. Zhang, Y. J. Liu, *et al.*, Simultaneous Quantification of Serum Nonesterified and Esterified Fatty Acids as Potential Biomarkers to Differentiate Benign Lung Diseases from Lung Cancer, *Sci Rep.*, 2016, **6**, 34201.
- 53 P. Petryszyn and A. Wiela-Hojenska, Economic Issues in Therapeutic Drug Monitoring, *Acta Pol. Pharm.*, 2016, **73**(3), 599–604.
- 54 Y. El Samad, J. P. Lanoix, Y. Bennis, *et al.*, Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections, *Antimicrob. Agents Chemother.*, 2016, **60**(10), 6365–6368.
- 55 J. Bai, J. T. Wang, K. C. Mei, *et al.*, Real-time monitoring of magnetic drug targeting using fibered confocal fluorescence microscopy, *J. Controlled Release*, 2016, **244**(Pt B), 240–246.
- 56 P. Herviou, E. Thivat, D. Richard, *et al.*, Therapeutic drug monitoring and tyrosine kinase inhibitors, *Oncol. Lett.*, 2016, **12**(2), 1223–1232.
- 57 J. M. Garcia Ruiz de Morales, D. Pascual-Salcedo, F. Llinares Tello, *et al.*, Anti-tumor necrosis factor drug therapy: the usefulness of monitoring drug levels and anti-drug antibodies in clinical practice, *Med. Clin.*, 2016, **147**(9), 410–416.
- 58 Y. Mukai, K. Wada, M. Fujimoto, *et al.*, Long-term impact of therapeutic drug monitoring on the risk of hypoglycemia in HOCM patients on cibenzoline therapy, *Int. J. Clin. Pharmacol. Ther.*, 2016, **54**(10), 795–803.
- 59 X. Li, S. B. Yang, Y. P. Qiu, *et al.*, Urinary Metabolomics as a Potentially Novel Diagnostic and Stratification Tool for Knee Osteoarthritis, *Metabolomics*, 2010, **6**(1), 109–118.
- 60 C. M. Rebholz, B. Yu, Z. Zheng, *et al.*, Serum metabolomic profile of incident diabetes, *Diabetologia*, 2018, **61**(5), 1046–1054.
- 61 E. P. Diamandis, Cancer biomarkers: can we turn recent failures into success, *JNCI, J. Natl. Cancer Inst.*, 2010, **102**(19), 1462–1467.
- 62 S. E. Kern, Why your new cancer biomarker may never work: recurrent pattern and remarkable diversity in biomarker failure, *Cancer Res.*, 2012, **72**(23), 6097–6101.
- 63 A. Mullard, New drug costs US \$2.6 billion to develop, *Nat. Rev. Drug Discovery*, 2014, **13**, 877.
- 64 L. Dang, D. W. White, S. Gross, *et al.*, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, *Nature*, 2009, **462**, 739–744.
- 65 P. S. Ward, J. Patel, D. R. Wise, *et al.*, The common feature of leukemia associated IDH1 and IDH2 mutations is a neomorphicezyme activity converting α -ketoglutarate to 2-hydroxyglutarate, *Cancer Cell*, 2010, **17**, 225–234.
- 66 G. Kontostathi, J. Zoidakis, N. P. Anagnostou, *et al.*, Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring, *Expert Rev. Proteomics*, 2016, **13**(8), 731–745.
- 67 A. Hilgers and M. Schaefer, Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients, *Drugs - Real World Outcomes*, 2016, **3**(2), 209–221.
- 68 E. G. Armitag, F. J. Rupérez and C. Barbas, Metabolomics of diet-related diseases using mass spectrometry, *TrAC, Trends Anal. Chem.*, 2013, **52**, 61–73.
- 69 T. L. Archibald, D. E. Murrell and S. D. Brown, Chromatographic methods in HIV medicine: application to therapeutic drug monitoring, *Biomed. Chromatogr.*, 2018, **32**(2), e4170.
- 70 M. Khoubnasabjafari, E. Rahimpour and A. Jouyban, Exhaled breath condensate as an alternative sample for drug monitoring, *Bioanalysis*, 2018, **10**(2), 61–64.
- 71 D. Ternant, C. Passot, A. Aubourg, *et al.*, Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration, *Clin. Pharmacokinet.*, 2018, **57**(9), 1173–1184.
- 72 A. R. Reinink, A Pharmacokinetic Rationale for Proactive Therapeutic Drug Monitoring of Anti-TNF Drugs, *Am. J. Gastroenterol.*, 2017, **112**(12), 1892–1893.



- 73 M. Guasch-Ferre, S. N. Bhupathiraju and F. B. Hu, Use of Metabolomics in Improving Assessment of Dietary Intake, *Clin. Chem.*, 2018, **64**(1), 82–98.
- 74 E. E. McGee, R. Kiblawi, M. C. Playdon, *et al.*, Nutritional Metabolomics in Cancer Epidemiology: Current Trends, Challenges, and Future Directions, *Curr. Nutr. Rep.*, 2019, **8**, 187–201.
- 75 S. Biswas, R. Mengji, S. Barman, *et al.*, 'AIE + ESIPT' assisted photorelease: fluorescent organic nanoparticles for dual anticancer drug delivery with real-time monitoring ability, *Chem. Commun.*, 2017, **54**(2), 168–171.
- 76 P. Marquet, L. Albano, J. B. Woillard, *et al.*, Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients, *Pharmacol. Res.*, 2018, **129**, 84–94.
- 77 A. O'Gorman and L. Brennan, The role of metabolomics in determination of new dietary biomarkers, *Proc. Nutr. Soc.*, 2017, **76**(3), 295–302.
- 78 M. F. Silva, C. Ribeiro, V. M. F. Goncalves, *et al.*, Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: a brief review, *Biomed. Chromatogr.*, 2018, **32**(5), e4159.
- 79 Y. Sun, H. Jensen, N. J. Petersen, *et al.*, Concomitant monitoring of implant formation and drug release of in situ forming poly(lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging, *J. Pharm. Biomed. Anal.*, 2018, **150**, 95–106.
- 80 A. Tebani and S. Bekri, Paving the Way to Precision Nutrition Through Metabolomics, *Front. Nutr.*, 2019, **6**, 41.
- 81 C. Lanvers-Kaminsky, A. Ruffer, G. Wurthwein, *et al.*, Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial, *Ther. Drug Monit.*, 2018, **40**(1), 93–102.
- 82 C. E. Argoff, D. P. Alford, J. Fudin, *et al.*, Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations, *Pain Med.*, 2018, **19**(1), 97–117.
- 83 J. Theobald, X. Cheng, A. Ghanem, *et al.*, Monitoring cytochrome P450 activity in living hepatocytes by chromogenic substrates in response to drug treatment or during cell maturation, *Arch. Toxicol.*, 2018, **92**(3), 1133–1149.
- 84 S. A. Ranamukhaarachchi, C. Padeste, M. Dubner, *et al.*, Integrated hollow microneedle-optofluidic biosensor for therapeutic drug monitoring in sub-nanoliter volumes, *Sci. Rep.*, 2016, **6**, 29075.
- 85 Z. K. Ye, K. Chen, Y. L. Chen, *et al.*, A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin, *J. Huazhong Univ. Sci. Technol., Med. Sci.*, 2016, **36**(3), 469–472.
- 86 J. L. Ren, H. Sun, H. Dong, *et al.*, A UPLC-MS-based metabolomics approach to reveal the attenuation mechanism of Caowu compatibility with Yunnan Baiyao, *RSC Adv.*, 2019, **9**, 8926–8933.
- 87 B. G. J. Dekkers, M. Bakker, K. C. M. van der Elst, *et al.*, Therapeutic Drug Monitoring of Posaconazole: An Update, *Curr. Fungal Infect. Rep.*, 2016, **10**, 51–61.
- 88 L. Dalfino, F. Bruno and N. Brienza, Does the journey toward efficacy and safety of high dose beta-lactams pass through therapeutic drug monitoring?, *Minerva Anesthesiol.*, 2016, **82**(9), 923–925.
- 89 F. B. Xia, A. Li, Y. S. Chai, *et al.*, UPLC/Q-TOFMS-Based Metabolomics Approach to Reveal the Protective Role of Other Herbs in An-Gong-Niu-Huang Wan Against the Hepatorenal Toxicity of Cinnabar and Realgar, *Front. Pharmacol.*, 2018, **9**, 618.
- 90 P. C. Liang, Y. C. Chen, C. F. Chiang, *et al.*, Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy, *Int. J. Nanomed.*, 2016, **11**, 2021–2037.
- 91 G. Groeneveld, M. de Puit, S. Bleay, *et al.*, Detection and mapping of illicit drugs and their metabolites in fingerprints by MALDI MS and compatibility with forensic techniques, *Sci. Rep.*, 2015, **5**, 11716.
- 92 E. Germovsek, A. Kent, T. Metsvaht, *et al.*, Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants, *Antimicrob. Agents Chemother.*, 2016, **60**(8), 4869–4877.
- 93 M. Selwet, M. Galbas, R. Slomski, *et al.*, Monitoring of Virulence Genes, Drug-Resistance in *Campylobacter coli* Isolated from Golden Retrievers, *Pol. J. Microbiol.*, 2016, **65**(2), 237–240.
- 94 C. Jang, L. Chen and J. D. Rabinowitz, Metabolomics and Isotope Tracing, *Cell*, 2018, **173**(4), 822–837.

